Navigation Links
Stent for life initiative
Date:9/1/2009

Barcelona, Spain, 1 September: Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use. The Stents 4 Life initiative was a study aiming to analyze the use of primary angioplasty in the treatment of AMI in 27 European countries.

Data were collected from national infarction or angioplasty registries, on AMI epidemiology and treatment and on angioplasty centres and procedures in each country.

Findings showed that the frequency (annual incidence) of hospital admission for any AMI varied between 90 and 312 events per 100,000 population per year; the incidence of serious AMIs (with ST-elevations on ECG - STEMI) ranging from 44-142 per thousand.

Primary angioplasty (primary PCI) was the dominant reperfusion strategy in 17 countries and thrombolysis in nine countries. The application of a PCI strategy varied between 5 and 92% (in all STEMI patients), and use of thrombolysis (an older, less effective form of therapy) between 0 and 55%. Curent guidelines recopmmend that any reperfusion treatment (angioplasty or thrombolysis) should be used ideally in 100% of these patients; however, we found it used only in 37󈟉% of STEMI patients.

The number of primary angioplasty procedures per million population per year varied among countries between 20 and 970. The mean population served by a single primary angioplasty centre varied between 0.3 and 7.4 million inhabitants. In those coutries offering primary angioplasty services to most of their STEMI patients, population varied between 0.3 and 1.1 million per centre.

In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, of patients treated by thrombolysis between 3.5 and 14%, and of patients treated by primary PCI between 2.7 and 8%.

The time reported from symptom onset to the first medical contact (FMC) varied between 60 and 210 minutes, FMC to needle time for thrombolysis between 30 and 110 minutes, and FMC to balloon time for primary angioplasty between 60 and 177 minutes.

Most north, west and central European countries used primary angioplasty for the majority of their STEMI patients. The lack of organised primary angioplasty networks in some countries was associated with fewer patients overall receiving some form of reperfusion therapy. Primary angioplasty rates above 600 per million population are needed to provide this treatment for most STEMI patients in Europe.


'/>"/>

Contact: Jacquelline Partarrieu
jpartarrieu@escardio.org
0034-600-919-617
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
2. Adding a Stent May Help Resolve Brain Aneurysm
3. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
4. Stenting a Good Option for Left Main Heart Artery
5. Stent Studies Tied to Rapid Changes in Use
6. QHR Client Hospitals Lauded for Consistently High Quality Standards, Exceeding Patient Expectations
7. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
8. AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent
9. CorNova(R) Receives CE Mark Approval for Valecor Platinum(R) Coronary Stent System
10. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
11. Newest Coated Stent Does Well in Real-World Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a Makro ... list for its expertise in eClinical Solutions. DDi has built its solution competency ... needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory and ...
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... BURLINGAME, Calif. , Feb. 11, 2016  NOIT™ ... announced a special "Gift of Change" campaign to assist ... units. For every such unit sold between February 10, ... a unit to a needy family. The NOIT is ... helping non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology: